From 29 January – 1 February 2018 the TBVI symposium and TBVAC2020 annual meeting took place in Les Diablerets, Switzerland. This yearly event was attended by over 140 participants from 70 research institutes, universities, industry, funding and technical agencies.
The TBVI Symposium focused on therapeutic vaccination and host-directed (immuno) therapy against TB. The speakers’ presentations are available here.
The Annual meeting highlighted new results from the H2020 TBVAC2020 project that are advancing the TB vaccine R&D field including the identification of six novel TB vaccine candidates and promising signatures of protection were identified that contribute to innovate and diversify the vaccine pipeline.
The meeting once again clearly demonstrated the added value of a research consortium and partnership approach to advance the TB vaccine field.
TBVI would like to thank all the speakers and participants and speakers for their valuable contributions and hopes to welcome all to the 2019 meeting in Les Diablerets.